Comparative clinical effectiveness of azacitidineversusdecitabine in older patients with myelodysplastic syndromes-Reference-Cited by-同舟云学术

Comparative clinical effectiveness of azacitidineversusdecitabine in older patients with myelodysplastic syndromes

Published:2016-09-21 Issue:5 Volume:175 Page:829-840
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Zeidan Amer M.¹²,Davidoff Amy J.²³,Long Jessica B.²,Hu Xin²,Wang Rong²⁴,Ma Xiaomei²⁴,Gross Cary P.²,Abel Gregory A.⁵,Huntington Scott F.¹²,Podoltsev Nikolai A.¹,Hajime Uno⁵,Prebet Thomas¹^ORCID,Gore Steven D.¹²

Affiliation:

1. Department of Internal Medicine; School of Medicine; Yale University; New Haven CT USA

2. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center; Yale University; New Haven CT USA

3. Department of Health Policy and Management; School of Public Health; Yale University; New Haven CT USA

4. Department of Chronic Disease Epidemiology; School of Public Health; Yale University; New Haven CT USA

5. Division of Population Sciences; Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA USA

Funder

Dennis Cooper Hematology Young Investigator Award

National Cancer Institute

American Cancer Society

California Department of Public Health

Northern California Cancer Center

University of Southern California

Public Health Institute

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14305/fullpdf

Reference25 articles.

1. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes;Abou Zahr;Expert Review of Anticancer Therapy,2015

2. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry;Bernal;Leukemia,2015

3. Underreporting of myeloid malignancies by United States cancer registries;Craig;Cancer Epidemiology, Biomarkers & Prevention,2012

4. Comorbidity measures for use with administrative data;Elixhauser;Medical Care,1998

5. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;The Lancet. Oncology,2009

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond HMAs: Novel targets and therapeutic approaches;Seminars in Hematology;2024-08

2. Real‐world study of the use of azacitidine in myelodysplasia in Australia;eJHaem;2024-05-17

3. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities;Current Hematologic Malignancy Reports;2024-04-18

4. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review;Journal of Oncology Pharmacy Practice;2024-03-21

5. Venetoclax in combination with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia;Tropical Journal of Pharmaceutical Research;2024-02-05